book now
Logo&nsbp;
CO-LOCATED EVENTS

Speaker

Alex Bastian

Vice President, Commercial Strategy & BD, Memo Therapeutics AG

Alex Bastian is the VP of Commercial Strategy of Memo Therapeutics AG and is an experienced commercial leader in the biotech sector. He was formerly VP of Commercial & Patient Access at AM-Pharma, where he led market access for an innovative in-hospital therapy for acute kidney injury. Alex has also held various senior roles in big pharma including Pfizer and Amgen in addition to small biotech with Galapagos and Incyte Corporation in both Europe and the US. He is completing a Doctor of Public Health at the Johns Hopkins Bloomberg School of Public Health, USA, has an MBA from IESE Business School in Barcelona, Spain and a bachelor’s degree from the University of Minnesota, USA.

Join Alex Bastian
Book Now!

Session

Move Fast and Not Break Things – How to Run an Efficient and Decluttered Market Access Function?

Case Study

Monday, October 06

09:25 am - 09:50 am

Live in Berlin

Less Details

Being a smaller biotech has its advantages and disadvantages. However, when it comes to market access, we have been able to build an efficient and fast-moving function. Even though market access in the renal therapeutic area is complex, our structure helps us handle the challenges (high treatment costs, limited options, as well as challenges in reimbursement and healthcare infrastructure) in a better way.

In this presentation you will learn:

  • What advantages our smaller structure gives us
  • What other, larger companies, can learn from us
  • Agility and laser focus on what’s important – how to reach this mindset
  • How to overcome access challenges in the renal therapeutic area
Presentation

Company

Memo Therapeutics AG

https://memo-therapeutics.com/
Memo Therapeutics AG is a late-stage biotech company developing best-in-class therapeutic antibodies to transform the lives of patients with viral infections and cancer. Our lead program, potravitug, currently in Phase II development, is the most potent antibody ever tested in clinical trials to treat BK viremia in kidney transplant recipients. BK viremia can lead to nephropathy, loss of kidney function, as well as organ failure, rejection and death. Other programs consist of therapeutic antibodies focusing on novel oncology targets which we are developing both alone and in partnership.
Get Agenda
Book Now